Out of the different marker combinations, Reg3α and ST2 serum levels at the onset of GvHD, combined in an algorithm validated by the Mount Sinai Acute GvHD International Consortium (MAGIC), have been shown to be predictive of 6-month NRM independently of clinical severity at onset (78). This evidence concerns the gene REG3A and graft versus host disease.